- As expected, the European Commission clears AstraZeneca's (NYSE:AZN) TAGRISSO (osimertinib) 80 mg once-daily tablets for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer.
- TAGRISSO received a positive advisory committee endorsement in December.
- Previously: AstraZeneca keeping Europe's CHMP busy with three positive reviews (Dec. 18, 2015)
AstraZeneca's TAGRISSO approved in Europe
Recommended For You
About AZN Stock
Related Stocks
| Symbol | Last Price | % Chg |
|---|---|---|
| AZN | - | - |
| AstraZeneca PLC | ||